The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | SOHO-02: BAY 2927088, an oral HER2 TKI, for first-line NSCLC
Antonio Passaro, MD, PhD, Istituto Europeo di Oncologia, Milan, Italy, discusses the Phase I/II SOHO-02 trial (NCT06452277) of BAY 2927088, an oral HER2 tyrosine kinase inhibitor (TKI), as a first-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations. The study randomizes patients to BAY 2927088 or pembrolizumab plus platinum-based chemotherapy, the standard of care. Primary endpoints include progression-free survival, and secondary objectives include overall survival, response rates, and safety. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
